Background Published economic assessments of rotavirus vaccination typically use modelling, mainly static Markov cohort models with birth cohorts followed up to the age of 5 years. Rotavirus vaccination has now been available for several years in some countries, and data have been collected to evaluate the real-world impact of vaccination on rotavirus hospitalisations. This study compared the economic impact of vaccination between model estimates and observed data on disease-specific hospitalisation reductions in a country for which both modelled and observed datasets exist (Belgium). Methods A previously published Markov cohort model estimated the impact of rotavirus vaccination on the number of rotavirus hospitalisations in children aged <5 years in Belgium using vaccine efficacy data from clinical development trials. Data on the number of rotavirus-positive gastroenteritis hospitalisations in children aged <5 years between 1 June 2004 and 31 May 2006 (pre-vaccination study period) or 1 June 2007 to 31 May 2010 (post-vaccination study period) were analysed from nine hospitals in Belgium and compared with the modelled estimates. Results The model predicted a smaller decrease in hospitalisations over time, mainly explained by two factors. First, the observed data indicated indirect vaccine protection in children too old or too young for vaccination. This herd effect is difficult to capture in static Markov cohort models and therefore was not included in the model. Second, the model included a ‘waning’ effect, i.e. reduced vaccine effectiveness over time. The observed data suggested this waning effect did not occur during that period, and so the model systematically underestimated vaccine effectiveness during the first 4 years after vaccine implementation. Conclusions Model predictions underestimated the direct medical economic value of rotavirus vaccination during the first 4 years of vaccination by approximately 10% when assessing hospitalisation rates as compared with observed data in Belgium.
References
[1]
Standaert B, Parez N, Tehard B, Colin X, Detournay B (2009) Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy 6: 199–216.
[2]
Martin A, Batty A, Roberts JA, Standaert B (2009) Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 27: 4520–4528.
[3]
Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, et al. (2011) Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health 11: 462.
[4]
Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, et al. (2009) The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine 27: 6121–6128.
[5]
Dewar DM (2009) Essentials of Health Economics. 1st ed. Burlington, MA: Jones & Bartlett Learning.
[6]
Garnett GP (2002) An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect 78: 7–12.
[7]
Atchison C, Lopman B, Edmunds WJ (2010) Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 28: 3118–3126.
[8]
Atkins KE, Shim E, Pitzer VE, Galvani AP (2012) Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 30: 552–564.
[9]
Lopman BA, Curns AT, Yen C, Parashar UD (2011) Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 204: 980–986.
[10]
Van Effelterre T, Soriano-Gabarro M, Debrus S, Newbern EC, Gray J (2010) A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 138: 884–897.
[11]
Desselberger U, Huppertz HI (2011) Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis 203: 188–195.
Bilcke J, Beutels P (2009) Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 27: 281–297.
[14]
Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, et al. (2007) Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370: 1757–1763.
[15]
Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, Esparza-Aguilar M, Johnson B, et al. (2010) Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 362: 299–305.
[16]
do Carmo GM, Yen C, Cortes J, Siqueira AA, de Oliveira WK, et al. (2011) Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med 8: e1001024.
[17]
Tate JE, Cortese MM, Payne DC, Curns AT, Yen C, et al. (2011) Uptake, impact, and effectiveness of rotavirus vaccination in the United States: review of the first 3 years of postlicensure data. Pediatr Infect Dis J 30: S56–S60.
[18]
Raes M, Strens D, Vergison A, Verghote M, Standaert B (2011) Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J 30: 120–125.
[19]
Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H (2010) Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J 29: 319–323.
[20]
Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, et al. (2011) Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico. Pediatr Infect Dis J 30: S11–S15.
[21]
Raes M, Strens D, Vergison A, Verghote M, Standaert B. (2011) Third year post-rotavirus vaccination in Belgium: impact on rotavirus-positive stool samples in hospitalised children. Presented at European Society for Paediatric Infectious Diseases (ESPID) 29th annual meeting, The Hague, Netherlands, 7–11 June 2011. Available: http://www.kenes.com/espid2011/cd/pdf/O1？18.pdf. Accessed 2012 Jun 15.
[22]
Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, et al. (2011) Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 30: S25–S29.
[23]
Fruytier A, Van Schoor J, Standaert B (2006) Vaccination with RIX4414 is cost-effective in a Belgian setting (abstract PIH3). Value Health 9: A253.
[24]
Melliez H, Boelle PY, Baron S, Mouton Y, Yazdanpanah Y (2005) Morbidite et cout des infections a rotavirus en France [Morbidity and cost of rotavirus infections in France]. Med Mal Infect 35: 492–499.
[25]
Standaert B, Harlin O, Desselberger U (2008) The financial burden of rotavirus disease in four countries of the European Union. Pediatr Infect Dis J 27: S20–S27.
[26]
Harris JP, Jit M, Cooper D, Edmunds WJ (2007) Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 25: 3962–3970.
[27]
Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, et al. (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354: 23–33.
[28]
Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, et al. (1996) Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335: 1022–1028.
[29]
Fischer TK, Valentiner-Branth P, Steinsland H, Perch M, Santos G, et al. (2002) Protective immunity after natural rotavirus infection: a community cohort study of newborn children in Guinea-Bissau, west Africa. J Infect Dis 186: 593–597.
